Matinas BioPharma

This biopharmaceutical is more about a new drug delivery platform than it is about drugs.

It is working on a drug for people who have dyslipidemia, or abnormally high triglycerides or cholesterol. It delivers omega-3 fatty acids to lower lipid counts more effectively than other methods using its proprietary platform.

Its platform is known as Lipid Nano-Crystal (LNC), and it allows drugs that would otherwise be highly toxic in the blood to be delivered to the cells that require treatment. This could have a significant impact on how drugs are delivered for a variety of diseases.

SunTrust has just started covering the stock, which has a market cap of $177 million. MTNB is down 61 percent year to date, indicating that it is inexpensive and has more upside than downside ahead of it.

Website: www.matinasbiopharma.com

Market Cap: 153.536M